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ABSTRACT
Purpose: To assess Eritrea’s progress towards elimination of trachoma as a public health problem,
we reviewed and compiled current knowledge on the distribution and burden of trachoma in
Eritrea, then undertook further population-based surveys where indicated, with support from the
Global Trachoma Mapping Project (GTMP).
Methods: For the systematic review, undertaken in March 2014, we searched (1) PubMed, using
the terms ((blind* or trachoma or trichiasis) AND Eritrea); (2) the online database of rapid
assessments of avoidable blindness; (3) our own grey literature collections; and (4) the Global
Atlas of Trachoma database. In June and July 2014, we conducted nine population-based
prevalence surveys, for each of which 30 villages were systematically selected with probability
proportional to population size; in each village, 30 households were systematically selected. All
consenting residents of selected households aged ≥1 year were examined by GTMP-certified
graders for signs of trachoma. Data on household-level access to water and sanitation were also
collected.
Results: One previous rapid assessment of avoidable blindness, three peer-reviewed publications,
and two grey literature reports detailing sets of trachoma prevalence surveys conducted in 2006
and 2011, respectively, were located. Post-intervention impact surveys were needed in seven
evaluation units (EUs, framed at sub-Zoba-level: population range 40,000–120,000) of Debub and
Northern Red Sea, while baseline surveys were needed in two EUs of Anseba. Four of the seven
impact survey EUs and both baseline survey EUs returned trachomatous inflammation—follicular
prevalences in 1–9-year-olds of ≥5%; six of the seven impact survey EUs and one of the two
baseline survey EUs returned trichiasis prevalences in ≥15-year-olds of ≥0.2%. The prevalence of
access to water and sanitation varied widely between EUs.
Conclusion: Interventions are still required in Eritrea to eliminate trachoma as a public health
problem. Data from these surveys will guide the Ministry of Health to undertake programme
planning using a sound evidence base.
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Introduction
Trachoma is an eye disease caused by particular
strains1,2 of the bacterium Chlamydia trachomatis. It
is strongly associated with poverty.3 In 2016, approxi-
mately 190 million people were thought to live in
endemic areas globally,4 where transmission of
C. trachomatis from eye to eye is believed to occur via
eye-seeking flies, fingers and fomites.5 Recurrent epi-
sodes of active (inflammatory) trachoma in children
can produce trachoma’s blinding complication, trichia-
sis, in later life.6–8
The World Health Organization (WHO) defines
“elimination of trachoma as a public health problem”
as a prevalence of the active trachoma sign “trachoma-
tous inflammation—follicular” (TF)9 among 1–9-year-
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olds of <5%, and a prevalence of trichiasis unknown to
the health system10 among ≥15-year-olds of <0.2%, in
every previously-endemic district.11 Achieving this
worldwide would constitute the Global Elimination of
Trachoma as a public health problem, which is targeted
for completion by the end of the year 2020
(GET2020).12,13
Trachoma is recognized to be an endemic disease in
Eritrea.14 Located in the Horn of Africa, the country is
bordered by the Red Sea to the east, Djibouti to the
south-east, Ethiopia15,16 to the south, and Sudan17 to
the north and west. It is divided into six regions
(Zobas) and has an estimated total population of
3.8 million people. Zobas are divided into a total of
58 districts (sub-Zobas), each of which has a population
of 40,000–120,000 people.
WHO recommends that surveys to determine
whether or not public-health-level interventions are
needed against trachoma normally be conducted in
evaluation units (EUs) of 100,000–250,000 people.
(This usually corresponds to the unit of administration
for healthcare.10) WHO further recommends that base-
line surveys may be done in larger EUs than this, in
order to get programmes started.10 Prior to 2014, some
baseline trachoma surveys had already been completed
in Eritrea, and interventions had been ongoing since
2011 in eight sub-Zobas.
The purpose of this work, undertaken in 2014, was
to review and compile current knowledge on the dis-
tribution and burden of trachoma in Eritrea, then to
conduct population-based surveys where indicated,
with support from the Global Trachoma Mapping
Project.18–21 In each EU that needed to be surveyed,
we used internationally-standardized approaches to
determine the prevalence of trichiasis in adults aged
≥15 years, the prevalence of TF in children aged 1–-
9 years, and prevalence of access to improved water and
sanitation.22
Methods
We undertook work in two phases. First, we carried out
a systematic review to consolidate what was already
known about the epidemiology of trachoma in Eritrea.
A PubMed (https://www.ncbi.nlm.nih.gov/pubmed/)
search was conducted for articles containing informa-
tion on trachoma epidemiology in the country, pub-
lished in any language prior to the search date of
7 March 2014. We used search terms ((blind* or tra-
choma or trichiasis) AND Eritrea). We supplemented
this with a search of the online database of rapid
assessments of avoidable blindness (http://raabdata.
info/repository/), review of relevant grey literature
held by the authors, and review of the data from
Eritrea held by the Global Atlas of Trachoma (www.
trachomaatlas.org23,24) as of 7 March 2014.
Second, guided by the results of the first phase, we
implemented a series of cross-sectional surveys using
two-stage cluster sampling in a total of nine EUs: seven
sub-Zobas of Debub and Northern Red Sea (where
impact surveys were due) and two EUs in Anseba
Zoba (where sufficiently detailed baseline data were
not available: see below).
Sample size
Sample-size calculations were determined based on
TF considerations, as recommended by WHO.25 The
EU-level sample size for baseline surveys is based on
an expected TF prevalence in 1–9-year-olds of 10%
and desired absolute precision of 3%. Using the sin-
gle-population-proportion-for-precision formula26
with a design effect of 2.65, to have 95% confidence
of estimating a prevalence of 10% ± 3%, 1019 chil-
dren are needed.19 The EU-level sample size for
impact surveys is based on an expected TF prevalence
in 1–9-year-olds of 4% and desired absolute precision
of 2%.10 Using the same formula and a design effect
of 2.65, to have 95% confidence of estimating
a prevalence of 4% ± 2%, 978 children are needed.
Inflating these figures by a factor of 1.2 to account for
non-response, we aimed to sample enough house-
holds to be able to enumerate 1222 resident children
(baseline EUs) or 1174 resident children (impact sur-
vey EUs).
Sampling plan
The first-stage sampling units were villages (popula-
tion range 100–1000 people). The sampling frame was
the list of all villages obtained from Eritrea’s Ministry
of Local Government; 30 were systematically selected,
with probability that was proportional to village popu-
lation size.25 In each selected village, 30 households
were selected, as follows. In small villages, the list of
households was obtained from village administrators
and households were systematically selected. In large
villages, four zones were created, one zone was drawn
at random, then the small-village selection method
was undertaken. Although children aged 1–9 years
and adults aged ≥15 years were the age groups of
interest, to enhance community acceptability, reduce
the amount of explanation that field teams had to
provide, and avoid creating incentives for age misre-
presentation, in selected households, we included all
residents aged ≥1 year.
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Team training and data collection
Survey teams comprised one ophthalmic clinical offi-
cer, one recorder and one driver. Team preparation was
undertaken in accordance with version 2 of the stan-
dard GTMP training system.27
All residents aged ≥1 year in sampled households
were enumerated and asked to agree to be examined for
signs of trachoma. Household-level data on location
(using GPS coordinates) and access to water and sani-
tation were also recorded. Teams moved from one
selected household to the next. Findings were recorded
in LINKS-GTMP19,28 on Android smartphones.
Data management
Data were encrypted and uploaded to a cloud-based
server, and managed according to standard GTMP
protocols, as previously described.19 However, because
available census data provided age breakdowns only in
5-year age bands, we initially undertook age standardi-
zation of TF prevalence estimates using age bins of 1–4
and 5–9 years, and the assumption that 1–4-year-olds
comprise 80% of the 0–5-year-old population. For the
purposes of this publication, we have also undertaken
age standardization of TF prevalence estimates using
1-year age bands, as employed elsewhere.29,30 In each
case, the proportion of 1–9 year-olds with TF in each
village was adjusted using the relevant age bands.
Similarly, the proportion of ≥15-year-olds with trichia-
sis was adjusted in 5-year age and gender bands. These
adjustments were intended to partially compensate for
incomplete examination recruitment in different age
and gender groups.31 EU-level prevalence estimates of
TF and trichiasis were calculated as the arithmetic
means of adjusted village-level proportions of TF and
trichiasis, respectively.
Ethical considerations
Informed written consent was obtained from the head
of the household to enter and work in each compound.
Owing to low levels of literacy and in accordance with
local norms, informed verbal consent was obtained for
examination. Examiners cleaned their hands with alco-
hol-based hand gel between each examination, to avoid
transferring pathogens between examinees. Individuals
with conjunctivitis were treated with 1% tetracycline
eye ointment. Individuals needing trichiasis surgery
were referred to the Zoba or sub-Zoba hospital where
they were offered management by the resident ophthal-
mologist, ophthalmic officer or trichiasis surgeon.
Other medical problems were managed in the field or
referred, as appropriate. Each work was conducted in
accordance with the principles of the Declaration of
Helsinki. Approval was obtained from the ethics com-
mittee of the London School of Hygiene & Tropical
Medicine (6319 and 8355) and the Eritrea Ministry of
Health National Ethics Committee.
Results
Systematic review
Our PubMed search returned 14 papers, only one of
which14 provided data on prevalence of trachoma gen-
erated since the 1987 publication9 of the WHO simpli-
fied trachoma grading system. (The same study was
also found in the database of rapid assessments of
avoidable blindness, as the only Eritrea-related work
stored there.) In 2008, Müller et al14 deployed survey
teams to 66 villages systematically selected with prob-
ability proportional to village size from a list of all
villages in Eritrea. Compact segment sampling was
used to select 50 people aged ≥50 years in each village.
Amongst 3163 people examined, 386 (12.3%) were
bilaterally blind or severely visually impaired; 4 (1.0%)
of these had their loss of vision attributed to
trachoma.14
Two earlier published papers, published in 196332
and 1964,33 held some data on trachoma that may now
be of only limited value, by virtue of their epidemiolo-
gical power and/or vintage. In 1963, Renna reported
results of investigations in the Eastern lowlands of
Eritrea in an area surrounding Massaua; the
MacCallan trachoma grading system34 was used to
evaluate 485 1–4-year-olds and 1098 5–14-year-olds,
finding signs of active trachoma in 194 (40%) and 411
(37%) of those groups, respectively.32 Vozza et al. com-
pleted a survey in 1960 in 10 villages of Serayé, a former
province of Eritrea that in the 1996 reclassification was
divided by the border created between the Zobas of
Debub and Gash-Barka. They found one or more
signs of trachoma in 97% of 5015 persons examined;
the prevalence of trichiasis in the all-ages population
was estimated to be 7%.33
Our own grey literature collections included
reports of two tranches of trachoma prevalence sur-
veys. In 2006, the Eritrea Ministry of Health under-
took trachoma surveys in Debub, Gash-Barka, and
Northern Red Sea. A total of three EUs were sur-
veyed, with each one framing the entirety of a Zoba.
In each EU, 30 households were enrolled from each
of 20 villages.35 Results are shown in Table 1 and
Figure 1. These surveys were adequately powered for
making decisions regarding intervention at EU level;
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further division of the data (to calculate 12, 14 and
nine sub-Zoba-level prevalence estimates for Debub,
Gash-Barka and Northern Red Sea, respectively)
probably introduces excessive imprecision, and those
estimates are therefore not reported here. It is impor-
tant to note, however, that on the basis of those
calculations, one sub-Zoba of Debub (May-Mine,
bordering Tigray Region of Ethiopia15 to the south)
was deemed to have a TF prevalence in 1–9-year-olds
of >30%.35
Interventions against trachoma, including mass
distribution of the antibiotic azithromycin, were
undertaken from 2011 to 2013 in all eight sub-
Zobas of Debub and Northern Red Sea thought to
have TF prevalence ≥10%, based on the 2006 survey
data.35 By 2014, impact surveys were needed in seven
of the eight; the other (May-Mine) was already pro-
grammed for two further years of intervention before
an impact survey was due.
The second tranche of surveys was conducted by the
Ministry of Health in 2011 in the remaining three Zobas
(Anseba, Maekel and Southern Red Sea) of Eritrea.
Surveys were powered to determine prevalence of TF
across the three Zobas as a single EU, with a total of
1135 1–9-year-olds examined. Results are shown in
Table 2 and Figure 1.36 Though the TF prevalence in
1–9-year-olds was <5%, it is difficult to have confidence
that active trachoma was rare or absent in any given sub-
Zoba, since the surveys were not powered to estimate
prevalence at that level. However, neither Maekel (which
contains Asmara and its surrounds) nor Southern Red Sea
was considered by the Ministry of Health prior to the
surveys as being likely to have trachoma as a public health
problem. Individuals aged 10–39 years were not exam-
ined, and trichiasis prevalence was determined in ≥40-
year-olds (Table 2). It has been estimated that a general
conversion factor for translating a trichiasis prevalence in
≥15-year-olds to one for ≥40-year-olds is ×2.5,37 meaning
Table 1. Sampling details and prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds and trichiasis in ≥15-year-
olds, Ministry of Health trachoma surveys, Eritrea, 2006.35
1–9-year-olds ≥15-year-olds
Zoba
Number of villages (households)
sampled
Number
examined
TF prevalence, %a (95%
CI)
Number
examined
Trichiasis prevalence, %a (95%
CI)
Debub 20 (600) 952 14.9 (12.7–17.4) 1198 2.2 (1.5–3.2)
Gash-
Barka
20 (604) 1125 2.4 (1.6–3.5) 1270 1.9 (1.3–2.9)
NRS 20 (601) 841 5.5 (4.1–7.3) 1046 1.1 (0.6–1.9)
aUnadjusted (original datasets unavailable).
CI, confidence interval; NRS, Northern Red Sea.
Figure 1. Prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds, trachoma prevalence surveys, Eritrea, 2006
(Debub, Gash-Barka, and Northern Red Sea [NRS], each surveyed as a separate evaluation unit) and 2011 (Anseba, Maekel, and
Southern Red Sea [SRS], surveyed as a single [discontinuous] evaluation unit composed of all three zobas).
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that the equivalent trichiasis prevalence estimate in ≥15-
year-olds for this EU would be 0.6%. It is noted that the
proportion of children examined who had TF, and the
proportion of adults examined who had trichiasis, were
both considerably higher in Anseba than in the other two
Zobas.36We therefore planned further baseline surveys in
Anseba, as part of our second phase of work.
Global Trachoma Mapping Project surveys
We undertook survey fieldwork in June–July 2014 in the
nine sub-zobas identified to need trachoma prevalence
surveys: two repeat baseline surveys in Anseba, six impact
surveys inDebub, and one impact survey inNorthern Red
Sea. Across the nine EUs, 8059 households were visited,
and a total of 10,338 1–9-year-olds and 17,056 ≥15-year-
olds were enumerated. Of these, 9956 (96%) and 13,926
(82%), respectively, were examined (Table 3). The EU-
level prevalence of TF in 1–9-year-olds ranged from 1.6%
(95%CI 0.8–2.6) to 9.2% (95%CI 6.6–12.2) (Table 3,
Figure 2). The EU-level prevalence of trichiasis in ≥15-
year-olds ranged from 0.10% (95% CI 0.00–0.26) to 1.15%
(95%CI 0.73–1.66) (Table 3, Figure 3).
There was considerable variation between EUs in the
prevalence of household-level access to water and sanita-
tion (Table 4).
Discussion
Trachoma is still a public health problem in parts of
Eritrea. Both EUs of Anseba (a Zoba previously sur-
veyed in 2011 as part of a large, three-zoba EU)
Table 2. Sampling details and prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds and trichiasis in ≥40-year-
olds, Ministry of Health trachoma surveys, Eritrea, 2011.36
1–9-year-olds ≥40-year-olds
Evaluation
unit
Number of villages (households)
sampled
Number
examined
TF prevalence, %a (95%
CI)
Number
examined
Trichiasis prevalence, %a (95%
CI)
Anseba 7 (not stated) 452 3.8 (2.8–4.9) 169 1.5 (0.4–2.9)
Maekel 10 (not stated) 500 170
SRS 3 (not stated) 183 114
Total 20 (595) 1135 453
aUnadjusted (original datasets unavailable).
CI, confidence interval; SRS, Southern Red Sea.
Table 3. Number of 1–9-year-olds and number of ≥ 15-year-olds resident, examined, absent and refused; prevalence of trachoma-
tous inflammation—follicular (TF); and prevalence of trichiasis; trachoma prevalence surveys, Eritrea, June and July, 2014.
1–9-year-olds ≥15-year-olds
Evaluation unit
[Zoba, sub-Zoba
(s)] (label in
Figures 2 and 3)
Number of
villages
sampled Resident Examined Absent Refused
TF
prevalence,
%a (95% CI)
TF
prevalence,
%b (95% CI) Resident Examined Absent Refused
Trichiasis
prevalence,
%c (95% CI)
Anseba, Adi
Tekeliezan/
Elabared/
Gheleb/Hagaz
(1)
31 1380 1279 93 8 8.6
(6.1–11.4)
9.8
(7.1–12.8)
2282 1589 685 8 0.15
(0.06–0.27)
Anseba, Habero/
Halhal/
Hamelmalo/
Keren (2)
29 1269 1176 86 7 8.2
(5.5–10.5)
8.5
(5.9–11.0)
2086 1371 699 16 0.44
(0.14–0.74)
Debub, Adi Quala
(3)
30 1032 881 65 86 2.7 (1.7–3.6) 3.0 (1.9–3.9) 2497 1602 865 26 0.76
(0.51–1.04)
Debub, Areza (4) 30 1021 1021 0 0 8.6
(6.2–10.7)
10.7
(7.8–13.2)
1402 1315 87 0 0.65
(0.40–0.90)
Debub, Dubarwa
(5)
30 1097 1097 0 0 9.2
(6.6–12.2)
10.4
(7.8–13.5)
1538 1454 82 2 0.74
(0.28–1.57)
Debub, Emni Haili
(6)
30 1547 1524 19 1 6.9 (5.4–8.9) 7.8 (6.3–9.9) 2087 1998 86 3 0.60
(0.36–0.85)
Debub,
Mendefera (7)
30 1019 1008 4 7 5.6 (4.2–7.6) 7.4
(5.3–10.2)
1616 1609 1 5 1.14
(0.77–1.53)
Debub, Sena’fe (8) 30 858 858 0 0 1.6 (0.8–2.6) 1.8 (1.0–2.8) 1670 1593 75 2 1.15
(0.73–1.66)
Northern Red Sea,
Nakfa (9)
30 1115 1112 3 0 2.6 (1.6–4.1) 2.8 (1.8–4.0) 1878 1395 483 0 0.10
(0.00–0.26)
Totals 270 10,338 9956 270 109 17,056 13,926 3063 62
aAdjusted for age in 1–year age bands (see text).
bAdjusted for age against the age bands 1–4 years and 5–9 years (see text).
cAdjusted for gender and age in 5–year age bands (see text).
CI, confidence interval; N/A, not applicable.
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returned 2014 baseline TF prevalence estimates in 1–-
9-year-olds indicating a need for intervention with the
A, F and E components of the SAFE strategy.38,39 One
of those two Anseba EUs also had a trichiasis preva-
lence in adults above the 0.2% elimination threshold,
and will therefore need public-health-level implemen-
tation of the S component of SAFE.11 Of the seven
EUs in which we completed impact surveys, three had
TF prevalences <5% and now enter the two-year active
trachoma surveillance period,11,40 while the other four
require ongoing A, F and E interventions. Only one of
the seven impact survey EUs (Nafka sub-Zoba of
Northern Red Sea) had a trichiasis prevalence in
adults <0.2%.
Figure 2. Prevalence of trachomatous inflammation—follicular (TF) in 1–9-year-olds, trachoma prevalence surveys, June and July,
2014. Sub-Zobas are labelled with numbers; the key is found in both Tables 3 and 4. (NRS, Northern Red Sea; SRS, Southern Red Sea).
Figure 3. Prevalence of trichiasis in ≥15-year-olds, trachoma prevalence surveys, Eritrea, June and July, 2014. Sub-Zobas are labelled
with numbers; the key is found in both Tables 3 and 4. (NRS, Northern Red Sea; SRS, Southern Red Sea).
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Because available Eritrea census publications report
age-specific data for the bands 1–4 years and 5–9 years,
we initially undertook age standardization of TF esti-
mates against those two broad divisions. Elsewhere in
similar circumstances, the GTMP developed a practice
of evenly sub-dividing such totals into one-year age
bands and age-standardizing against the result, using
the rationale that ignoring mortality from 12 to
59 months and from 60 to 119 months would be
preferable to ignoring the (often substantial) differ-
ences in age-specific TF prevalence within these age
brackets. We therefore undertook repeat analysis
using one-year age band standardization for the pur-
poses of compiling this manuscript. For Areza and
Dubarwa sub-Zobas in Debub, standardizing against
broader and finer age bands gave programmatically
different TF prevalence estimates. For both EUs, the
TF prevalence was determined to be within the
5.0–9.9% range using the finer age bands, and just
greater than 10% using the broader ones. Although
the confidence intervals for these paired alternate esti-
mates had considerable overlap, the distinctions are
functionally important, because EUs in which TF pre-
valence is 10.0–29.9% qualify for three years of annual
mass antibiotic treatment, whereas WHO recom-
mends only that targeted antibiotic treatment be con-
sidered in EUs in which TF prevalence is 5.0–9.9%.25
(Recent data suggest that a single round of mass treat-
ment may be effective for EUs in that prevalence
range.41) Further work to determine the most appro-
priate way to undertake age standardization of TF
prevalence estimates may be needed.
The data reported here have other deficiencies. We
did not examine for the presence or absence of tracho-
matous scarring9 in tarsal conjunctivae of eyes with
trichiasis.42 The extremely high proportion of resident
children apparently examined (Table 3) suggests that
field teams either enumerated only those present at the
time of the visit or were assiduous in returning at the
end of the day to examine children who were initially
absent; our field supervisors believe the latter explana-
tion is correct. (This belief is supported by the fact that
many absentee adults were enumerated.) In Sena’fe
sub-Zoba, only 858 1–9-year-olds were examined: 88%
of the 978 targeted, though availability of data from 30
(rather than fewer) clusters and the relatively tight
confidence intervals suggest that the TF prevalence
estimate here would be reproducible. There were large
differences in the numbers of absentee adults recorded
between EUs, an observation for which we also lack
a definitive explanation. Finally, GPS satellite fixes43
were frequently elusive, and many houses therefore
lacked GPS coordinate information, limiting our ability
to quality-assure household selection.44
These were not easy surveys. First, selected villages
were often very hard to reach, with terrain that did
not allow vehicle access. Field teams were forced to
start work early and travel on foot for several hours
to reach the villages of interest. Second, delays occa-
sioned by difficulties in transferring financial
resources into the country meant that fieldwork com-
menced at the onset of the rainy season. Potential
examinees were therefore busy with time-sensitive
planting activities, and our graders and recorders
had to find them in nearby fields. These timing issues
made making return visits to households (to find
people absent at the time of the first visit)
a challenge. Third, crippling power shortages and
limited bandwidth complicated the process of data
upload-to-cloud in Asmara. We are proud of the
commitment of our teams in having successfully
completed the work despite these hurdles.
There remain a few sub-Zobas from the 2006 baseline
surveys in which TF or trichiasis prevalence estimates were
calculated (with wide confidence intervals, based on rela-
tively few sampled clusters) to be above elimination thresh-
olds. Eventually, to facilitate completion of a dossier
claiming elimination of trachoma as a public health
Table 4. Household-level access to improved water and sanitation facilities by evaluation unit, trachoma prevalence surveys, Eritrea,
June and July, 2014.
Evaluation unit [Zoba, sub-Zoba
(s)] (label in Figures 2 and 3)
Number of
households
enrolled, n
Access to (any source of) water for face-
washing within a 30-minute round trip, %
Access to an improved
source of drinking water, %
Access to
improved
sanitation, %
Anseba, Adi Tekeliezan/Elabared/
Gheleb/Hagaz (1)
925 70 80 46
Anseba, Habero/Halhal/
Hamelmalo/Keren (2)
870 77 54 29
Debub, Adi Quala (3) 901 79 76 3
Debub, Areza (4) 891 63 43 11
Debub, Dubarwa (5) 894 54 65 91
Debub, Emni Haili (6) 902 58 17 1
Debub, Mendefera (7) 873 61 38 20
Debub, Sena’fe (8) 900 80 50 53
Northern Red Sea, Nakfa (9) 903 69 57 3
OPHTHALMIC EPIDEMIOLOGY 127
problem from Eritrea,11 it may be necessary to re-survey
these sub-Zobas. Repeat surveys will also be necessary to
ensure that trachoma has been eliminated from EUs in
which more precisely estimated prevalence estimates sug-
gest that trachoma remains a public health problem. The
priority for this round of surveys was to undertake baseline
mapping in Anseba and to carry out the impact surveys in
Debub and Northern Red Sea. Completion of the systema-
tic review and nine population-based prevalence surveys
described here provides a check-in point for ongoing
efforts to eliminate trachoma from Eritrea. Such efforts
are an important part of the global programme, which is
now, following decades of work, starting to meet with
success.45
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